FDA Proposes Ban on Compounded Obesity and Diabetes Drugs, Names New Acting Director
The FDA proposed excluding semaglutide and tirzepatide from compounding lists, citing no clinical need. Katherine Szarama was named acting director of...
Xeber.world
obesity drugs
- electric vehicles
- automotive industry
- Stellantis
- collector cars
- automotive history
- Limited Edition
- classic cars
- Mecum Auctions
- supercar
- Formula 1
- Donald Trump
- AI ethics
- U.S. China relations
- AI adoption
- AI regulation
- artificial intelligence
- Trump administration
- inflation
- AI governance
- AI in business
- Bitcoin
- crypto regulation
- Senate Banking Committee
- CLARITY Act
- digital assets
- Digital Asset Market Clarity Act
- Federal Reserve
- Bitcoin price
- Bitcoin ETF
- crypto market
- AI cybersecurity
- cybersecurity
- CISA
- enterprise security
- CVE-2026-41089
- CVE-2026-41096
- Canvas data breach
- Instructure
- House Homeland Security Committee
- Donald Trump
- Netflix
- late-night TV
- Disney
- Paramount
- Cannes Film Festival
- Stephen Colbert
- Prime Video
- Jimmy Kimmel
- Marvel
- climate change
- renewable energy
- energy policy
- AI data centers
- geothermal energy
- Fervo Energy
- U.S. energy policy
- Strait of Hormuz
- Jason Bordoff
- Texas drought
- Subnautica 2
- Phasmophobia
- gaming news
- R.E.P.O.
- Forza Horizon 6
- FC 26
- Subnautica 2 tips
- Subnautica 2 guide
- Alan Wake event
- Destructoid
- FDA
- public health
- Marty Makary
- Trump administration
- healthcare policy
- Kyle Diamantas
- hantavirus
- health policy
- FDA leadership
- gene therapy
- Donald Trump
- Trump administration
- Supreme Court
- gerrymandering
- Iran war
- Voting Rights Act
- 2024 election
- Republican Party
- Virginia Supreme Court
- redistricting
- AI ethics
- climate change
- Elon Musk
- OpenAI
- ChatGPT
- tech industry
- Tesla
- remote sensing
- AI in the workplace
- generative AI
RFK Jr. Reverses Stance on Key MAHA Issues Amid Policy Shifts
Robert F. Kennedy Jr. has softened his position on certain MAHA-related policies, following challenges in implementing a Medicare pilot program for ob...
Medicare Postpones Obesity Drug Coverage Pilot Amid Biotech Updates on RevMed, Roche, and Kyverna CAR-T Therapy
Medicare has delayed a pilot program to cover obesity drugs for seniors, reversing a key healthcare initiative from the Trump administration. This com...
Medicare Scraps Obesity Drug Pilot After Insurer Pushback; Amazon Launches GLP-1 Access Program
The Trump administration's Medicare obesity drug pilot was abandoned after insurers declined to participate. Meanwhile, Amazon's One Medical is launch...